Entities / Company
Mylan.
former pharmaceutical company
- Reports this week
- 1
- Active events
- 3
- Connections
- 122
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Some support4 reports1 development inside
-
Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Some support1 report
-
The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.Some support4 reports
Earlier this month
One to three months ago
-
Pharmac made Mylan patches easier to access, a development that Martin subsequently discussed.Some support3 reports
-
Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.Some support1 report
-
Acquisition of TYRVAYA nasal spray from Viatris.Some support1 report
-
Mylan, a company, is headquartered in Canonsburg, PA, and its stock performance is benchmarked against the S&P 500.Some support1 report
-
Mylan faces annual sales erosion in developed markets, specifically North America and Europe.Some support1 report
-
Mylan plans to sell up to 92 million shares in Biocon.Some support1 report
-
The Protagonist worked at Viatris/Mylan for 33 years.Some support1 report
-
Viatris is headquartered in the U.S. and maintains global operational centers in Pittsburgh, Shanghai, and Hyderabad.Some support3 reports1 development inside
-
Mizuho Bank led lenders providing a loan to Viatris, which is headquartered in Pennsylvania and listed on Nasdaq.Some support1 report
-
IgAN is developing a targeted-release budesonide therapy, with an NDA submission targeted for the end of 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Mylan reached an exclusive multi-year commercial agreement with Shield Therapeutics plc for the U.S. launch of a product.Well supported3 reports
-
Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.Some support1 report1 development inside
-
Viatris gained China approval for the commercialization of Yupelri.Speculative1 report
-
Church & Dwight, Eli Lilly, and Viatris were all featured in Zacks Investment Ideas on September 4, 2025.Some support2 reports
-
Viatris and Microsoft were mentioned together as examples of diverse winners in thematic investing.Some support1 report
-
Michael Goettler, formerly of Viatris, was appointed to the Board of Directors of Bausch Health.Some support4 reports
-
Viatris was classified into the Zacks Medical Services industry as of August 7, 2025.Some support1 report
-
Viatris is involved in a development where Australia, New Zealand, and Japan are part of the JANZ segment.Some support1 report1 development inside
-
A market rally occurred on August 13, 2025, driven by positive inflation data, involving Viatris, Bruker, Sotera Health Company, Align Technology, and Omnicell.Some support1 report
-
Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.Some support1 report
-
Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.Some support2 reports
-
Viatris executives, including CFO Doretta Mistras and CEO Scott Smith, provided corporate guidance expectations and noted positive Phase III readouts on August 13, 2025.Some support1 report
-
Major pharmaceutical companies, including Johnson & Johnson, GlaxoSmithKline, and Viatris, are key players in the Paracetamol Market.Some support1 report
-
Viatris faced sales impacts due to government-driven price regulations and facility inspections at its Indore facility, affecting markets including Europe and North America.Some support1 report
-
Viatris is managing ongoing dialogues with the FDA, addressing investor queries regarding share repurchases, and reporting on operational growth in Europe and China.Some support2 reports1 development inside
-
Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production.Well supported4 reports1 development inside
-
Viatris appointed Andrew Enrietti to a new role in August 2025.Some support1 report
-
FDA approved Iron Sucrose Injection for Viatris on August 12, 2025.Some support2 reports
-
Viatris, headquartered in Canonsburg, Pennsylvania, lagged behind the S&P 500 Index and the Health Care Select Sector SPDR Fund on July 23, 2025.Some support1 report
-
Mylan merged with Pfizer's Upjohn division, which was part of Viatris, leading to volatility in the stocks of the involved companies.Well supported13 reports
-
Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.Some support2 reports
-
Viatris achieved Great Place To Work certification and established a presence in Canada, led by Jeffrey Long.Some support1 report
-
China approval on 2025-07-15 triggers a payment owed to Theravance Biopharma.Some support1 report
-
Philippe Martin was appointed Chief R&D Officer at Viatris in June 2025.Speculative1 report
-
Viatris stock significantly underperformed SPX and peer Sanofi on June 24, 2025.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Mylan this week
News at the entities that move Mylan most-
Pfizer StructuralDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Mylan
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Mylan
-
Teva Pharmaceutical Industries Ltd. OperationalTeva Pharmaceutical Industries Ltd. is being investigated by the Competition Authority regarding generic competition practices.Moves Mylan
-
Japan Shared contextSri Lanka joined the Sterling Assets Agreement and participated in the San Francisco Conference.Moves Mylan
-
SPX Mentioned togetherSoutheast, headquartered in Birmingham, is seeing its stock performance lag the S&P 500.Moves Mylan
-
Barclays Mentioned togetherQinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.Moves Mylan
Connections
The 25 strongest of 122, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Upjohn Structural
The relationship is structural, established by the 2020 merger of Mylan and Upjohn division.
-
Pfizer Structural
Mylan was absorbed into the corporate structure stemming from Pfizer's Upjohn division, leading to the formation of Viatris.
-
FDA Structural
FDA formally regulates Mylan's pharmaceutical products through inspections, protocols, and granting approvals.
-
Teva Pharmaceutical Industries Ltd. Operational
Teva and Mylan are direct competitors in the generic drug market and have been implicated in anti-competitive practices regarding generic release timelines.
-
Biocon Transactional
Mylan is currently planning the divestment of its 5.64% equity stake in Biocon.
-
Heron Operational
Heron and Mylan actively compete in the generic drug market and engage in licensing agreements.
-
Barclays Mentioned together
Barclays provides financial analysis and price targets regarding Mylan's (Viatris) quarterly results.
-
Zymeworks Operational
The evidence suggests a functional partnership where Zymeworks leverages market access provided by the entity currently operating under the Viatris umbrella, which is the operational successor to Mylan.
Show all 25 connections
-
SPX Mentioned together
Mylan's stock performance is frequently benchmarked against the gains of the S&P 500 index.
-
TD SYNNEX Shared context
Both companies are discussed in the context of small-cap value stocks targeted by ETFs.
-
Martin Mentioned together
Martin is cited as an expert discussing Mylan's patch accessibility issues.
-
Canonsburg Shared context
The company operates from its headquarters in Canonsburg.
-
Europe Shared context
Mylan's sales and performance are observed within the European market context.
-
Japan Shared context
Mylan's sales and market approval processes are governed by Japanese government regulations and reimbursement policies.
-
North America Shared context
Mylan operates within the North American market, which is characterized by annual sales erosion in developed markets.
-
Hyderabad Shared context
Viatris operates global centers within the city of Hyderabad.
-
Pittsburgh Shared context
Mylan maintains a global operational center in Pittsburgh.
-
American College of Cardiology Mentioned together
Both companies are mentioned as generic companies benefiting from the current regulatory climate.
-
Nasdaq Shared context
Mylan is a company listed on the Nasdaq stock exchange.
-
Shanghai Shared context
Viatris maintains global centers and operations within Shanghai.
-
Pennsylvania Shared context
Mylan's successor company, Viatris, is headquartered in Pennsylvania.
-
Harrow Borough F.C. Mentioned together
The provided evidence does not contain information linking Harrow Borough F.C. and Mylan.
-
Mizuho Bank Mentioned together
No evidence was provided linking Mizuho Bank and Mylan.
-
foundation Transactional
The relationship was observed through a specific instance where Viatris contributed as a major sponsor.
-
Martin Mentioned together
No direct relationship between Martin and Mylan was observed in the provided evidence timeline.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
4 events- Pharmac made Mylan patches easier to access, a development that Martin subsequently discussed.
- Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.
- Acquisition of TYRVAYA nasal spray from Viatris.
- Mylan, a company, is headquartered in Canonsburg, PA, and its stock performance is benchmarked against the S&P 500.
July 2026
5 events- Mylan faces annual sales erosion in developed markets, specifically North America and Europe.
- Mylan plans to sell up to 92 million shares in Biocon.
- The Protagonist worked at Viatris/Mylan for 33 years.
- Mizuho Bank led lenders providing a loan to Viatris, which is headquartered in Pennsylvania and listed on Nasdaq.
- IgAN is developing a targeted-release budesonide therapy, with an NDA submission targeted for the end of 2026.
Show 1 earlier month
June 2026
28 events- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Viatris is headquartered in the U.S. and maintains global operational centers in Pittsburgh, Shanghai, and Hyderabad.
- Mylan reached an exclusive multi-year commercial agreement with Shield Therapeutics plc for the U.S. launch of a product.
- Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.
- Viatris gained China approval for the commercialization of Yupelri.
- Church & Dwight, Eli Lilly, and Viatris were all featured in Zacks Investment Ideas on September 4, 2025.
- Viatris and Microsoft were mentioned together as examples of diverse winners in thematic investing.
- Michael Goettler, formerly of Viatris, was appointed to the Board of Directors of Bausch Health.
- Viatris was classified into the Zacks Medical Services industry as of August 7, 2025.
- Viatris is involved in a development where Australia, New Zealand, and Japan are part of the JANZ segment.
- A market rally occurred on August 13, 2025, driven by positive inflation data, involving Viatris, Bruker, Sotera Health Company, Align Technology, and Omnicell.
- Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.
- Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.
- Viatris executives, including CFO Doretta Mistras and CEO Scott Smith, provided corporate guidance expectations and noted positive Phase III readouts on August 13, 2025.
- Major pharmaceutical companies, including Johnson & Johnson, GlaxoSmithKline, and Viatris, are key players in the Paracetamol Market.
- Viatris faced sales impacts due to government-driven price regulations and facility inspections at its Indore facility, affecting markets including Europe and North America.
- Viatris is managing ongoing dialogues with the FDA, addressing investor queries regarding share repurchases, and reporting on operational growth in Europe and China.
- Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production.
- Viatris appointed Andrew Enrietti to a new role in August 2025.
- FDA approved Iron Sucrose Injection for Viatris on August 12, 2025.
- Viatris, headquartered in Canonsburg, Pennsylvania, lagged behind the S&P 500 Index and the Health Care Select Sector SPDR Fund on July 23, 2025.
- Mylan merged with Pfizer's Upjohn division, which was part of Viatris, leading to volatility in the stocks of the involved companies.
- Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.
- Viatris achieved Great Place To Work certification and established a presence in Canada, led by Jeffrey Long.
- China approval on 2025-07-15 triggers a payment owed to Theravance Biopharma.
- Philippe Martin was appointed Chief R&D Officer at Viatris in June 2025.
- Viatris stock significantly underperformed SPX and peer Sanofi on June 24, 2025.